Telix Pharmaceuticals Ltd at TD Cowen Healthcare Conference Transcript
Hi, everyone. I'm Tara Bancroft, one of the senior analysts here, and thank you for coming to TD Cowen's 46th Annual Healthcare Conference. For our next session, we have a presentation followed by some Q&A with Telix, and from Telix, we have the Group CEO, Christian Behrenbruch here. Thank you for joining us.
I'll let you go ahead with the presentation before we get started on the Q&A, so go ahead.
All right, well, thank you very much, Tara. I'll just step aside so you can actually see the screen. Just the usual preemptive statement, and I think most of you looking around the room recognize just about everybody. I think you understand the company, but just to give a sort of potted summary, 2026 is really about investing in developing our Therapeutics pipeline, which is very strong. We have three programs now that are in late-stage clinical trials, and that's where the majority of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
